Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors

Table 1

Evolution of analytical values during the admission of the patient.

Analytical values	HPS criteria	At time of admission	Baseline steroid therapy	Baseline tocilizumab	After 48 h of tocilizumab	At time of discharge
Hemoglobin (g/dL)	Yes	13.5	11.2	9.6	11.6	12.1
Platelets (/μL)	Yes	64.000	45.000	48.000	74.000	113.000
Ferritin (ng/mL)	Yes	>74.150	>74.150	>89.918	12.019	1978
Fibrinogen (mg/dL)	Yes	147	164	170	—	—
Triglycerides (mg/dL)	Yes	271	327	265	234	172
Bone marrow findings	Yes	—	—	Yes	—	No

– Not available.